<DOC>
	<DOCNO>NCT00005795</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine rate response ( complete partial remission ) , duration response , relapse free survival , overall survival patient relapse refractory acute myeloid leukemia ( AML ) untreated old patient secondary AML treat arsenic trioxide . II . Evaluate toxicity agent patient population . III . Measure degree apoptosis induce and/or differentiation pretreatment posttreatment AML cell . OUTLINE : Patients receive arsenic trioxide IV 1-4 hour daily 60 day , bone marrow blast less 5 % , follow 4-6 week rest . After first course , additional course arsenic trioxide last 25 day . Treatment continue maximum 6 course absence unacceptable toxicity disease progression . Patients complete response ( CR ) receive 1 additional 25 day course achieve CR . Patients follow monthly 6 month , every 2 month 6 month , every 3 month 12 month , every 6 month thereafter . PROJECTED ACCRUAL : A total 12-35 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Documented acute myelogenous leukemia ( AML ) include secondary AML biphenotypic leukemia Secondary AML may either chemotherapy induce evolve myelodysplastic syndrome Bone marrow evidence AML must include follow : Cellularity 20 % great Minimum 20 % leukemic cell Signs bone marrow failure : Anemia ( hemoglobin le 12.0 g/dL ) Granulocytopenia ( granulocyte count le 1,500/mm3 ) Thrombocytopenia ( platelet count le 100,000/mm3 ) Must follow : Acute lymphoblastic leukemia Blastic phase chronic myelogenous leukemia Acute promyelocytic leukemia ( M3 ) Prior induction therapy use conventional induction chemotherapy regimen require In first second relapse successful induction therapy OR Failed 1 attempt reinduction relapse OR Refractory least 1 prior induction therapy No prior induction therapy allow secondary AML newly diagnose AML patient least 65 year old PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : At least 6 week Hematopoietic : See Disease Characteristics No evidence platelet transfusion refractory WBC great 20,000/mm3 ( leukapheresis , hydroxyurea , allow ) Hepatic : Bilirubin great 2.0 mg/dL unless leukemic infiltration liver SGOT SGPT less 2 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No evidence symptomatic coronary atherosclerotic heart disease Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No active infection afebrile Afebrile , stable , complete antibiotic allow Febrile infection blood product allow PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent bone marrow transplantation Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No concurrent antileukemic agent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>